Physician profile
Mark E Cohen
NPI 1053470039
$1,581.04
in general payments reported to CMS, 2019-2025
12 companies · $90.87 in 2025
The $90.87 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2021: $57.57 · 2022: $950 · 2023: $172 · 2024: $156 · 2025: $90.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $972.21 | 2021-2023 | Bis |
| Sun Pharmaceutical Industries INC. | $185.76 | 2022-2025 | Winlevi, Absorica Ld, Blu-U |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2019 | |
| Merck Sharp & Dohme LLC | $72.50 | 2021-2023 | Bridion |
| Leo Pharma INC. | $71.08 | 2024 | Adbry |
| Chiesi USA, INC. | $57.02 | 2023-2025 | Cleviprex |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.18 | 2023 | Arazlo |
| Masimo Corporation | $32.39 | 2019 | |
| Daiichi Sankyo INC. | $17.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.39 | 2024 | Xarelto |
| Acelrx Pharmaceuticals, INC. | $13.70 | 2019 | |
| Biofrontera INC. | $12.06 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.